Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitors.

ABSTRACT:

Background & aims

While cancer survivorship for hepatocellular carcinoma (HCC) has improved, associated disease time burden in patients taking systemic therapies remains poorly understood. In this study, we used days at home (DAH), a patient-centered metric, to compare the disease time burden between patients taking immunotherapies and tyrosine kinase inhibitors (TKIs).

Methods

Patients with HCC receiving systemic therapy from 2008 to 2023 were identified from a population-based cohort. Patients were classified based on the use of immunotherapy (nivolumab, pembrolizumab, atezolizumab, durvalumab, tremelimumab, and ipilimumab; including monotherapies or combinations) or TKIs (lenvatinib, sorafenib, cabozantinib, and regorafenib). The primary outcome was DAH, defined as days a

SUBMITTER: Hui RW 

PROVIDER: S-EPMC12519240 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature